Magnesium-containing hydrogel with T cell activation activity as well as preparation method and application of magnesium-containing hydrogel

By combining nanomagnesium oxide particles with hydrogel, magnesium-containing hydrogels with T cell activation activity are prepared, which solves the problem of poor release of magnesium ions in bone defects and achieves rapid repair and regeneration of bone tissue. Provides better bone defect treatment effects.

CN118903537APending Publication Date: 2024-11-08PEKING UNIVERSITY SHENZHEN HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410964266.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing biological materials are difficult to controllable release of magnesium ions in bone defects, resulting in poor bone repair results and the triggered immune response affects the bone healing process.

Method used

Using nanomagnesium oxide particles to combine with hydrogel, a magnesium-containing hydrogel with T cell activation activity was prepared through the synergistic effect of T cell activator, which achieves the local slow release of magnesium ions and the activation of T cells, and regulates bone defects. immune response at the site.

Benefits of technology

It promotes rapid repair and regeneration of bone tissue, reduces treatment time and cost, reduces complication rate, and provides better bone defect repair results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903537A_ABST
    Figure CN118903537A_ABST
Patent Text Reader

Abstract

The invention provides magnesium-containing hydrogel with T cell activation activity as well as a preparation method and application of the magnesium-containing hydrogel, and belongs to the technical field of biological materials. The magnesium-containing hydrogel prepared by the invention has certain porosity, and can slowly release a T cell activator and magnesium ions into a living body at the same time to generate a bone repair effect. According to the invention, the nano magnesium oxide particles doped in the hydrogel can locally release magnesium ions; the existence of the T cell activating agent can promote the T cell activation of the bone defect part, so that the immune response reaction is enhanced; the biological environment of the bone defect part is regulated and controlled in a novel mode, specifically, the hydrogel can guide and regulate the immune response of the bone defect part in the initial stage through the synergistic effect of the nanometer magnesium oxide particles and the T cell activating agent, and bone tissue regeneration and repair are facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomaterials, and in particular to a magnesium-containing hydrogel with T cell activation activity, a preparation method and application thereof. Background Art

[0002] Bone tissue has the potential to self-repair and regenerate after trauma, but this healing process is not only time-consuming, but also difficult to completely restore the original structure and mechanical properties of bone tissue. Therefore, in clinical work, it is often necessary to transplant biomaterials to accelerate the bone healing process and maintain the final bone density. Current studies have shown that biomaterials implanted into bone defects will cause immune responses in the body. These responses can not only hinder the biomaterials from better exerting their osteogenesis, but also directly regulate the activation and differentiation of osteoblasts and osteoclasts and ultimately regulate bone formation.

[0003] In addition, as one of the most important trace elements in bone tissue and an indispensable active ingredient in systemic biological activities, magnesium ions are believed to play an important role in bone tissue repair. Past studies have shown that magnesium ions can affect bone repair by regulating macrophages in the immune system. For example, magnesium ions stimulate specific immune responses of macrophages through transient receptor potential channel M7 (TRPM7) kinase, playing a key role in the osteogenesis process.

[0004] However, it is difficult for existing biomaterials to release magnesium ions in a controllable manner, and their effect on bone repair needs to be further improved. Currently, researchers focus more on the innate immune response caused by biomaterials implanted into bone defects, and little research has been done on the effect of the adaptive immune response caused by the materials on bone defect repair. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a magnesium-containing hydrogel with T cell activation activity and a preparation method and application thereof. The magnesium-containing hydrogel with T cell activation activity provided by the present invention can realize local controlled release of magnesium ions and promote T cell activation, synergistically inducing the repair of bone defects.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for preparing a magnesium-containing hydrogel having T cell activation activity, comprising the following steps:

[0008] Mixing nano-magnesium oxide particles with a hydrogel raw material aqueous solution to obtain a hydrogel solution doped with magnesium oxide;

[0009] Adding calcium chloride solution to the magnesium oxide-doped hydrogel solution to solidify the solution into a gel to obtain a magnesium oxide-doped hydrogel;

[0010] The magnesium oxide-doped hydrogel is immersed in a T cell activator solution to obtain a magnesium-containing hydrogel having T cell activation activity.

[0011] Preferably, the hydrogel raw material includes one or more of collagen, gelatin, sodium alginate, polyacrylic acid and polyvinyl alcohol;

[0012] In the hydrogel raw material aqueous solution, the mass ratio of the hydrogel raw material to water is 0.001 to 30:100.

[0013] Preferably, the particle size of the nano magnesium oxide particles is 1 nm to 1 mm.

[0014] Preferably, the mass ratio of the nano-magnesium oxide particles to the hydrogel raw material aqueous solution is 0.001 to 20:100.

[0015] Preferably, the mass ratio of calcium chloride to water in the calcium chloride solution is 1 to 5:10;

[0016] The volume ratio of the calcium chloride solution to the hydrogel solution doped with magnesium oxide is 0.1 to 20:100.

[0017] Preferably, the curing temperature is 0 to 50° C. and the curing time is 0 to 30 minutes.

[0018] Preferably, the T cell activator solution is a mixed aqueous solution of anti-CD3 antibody, anti-CD28 antibody and interleukin-2;

[0019] In the T cell activator solution, the concentration of anti-CD3 antibody is 0.01-500 μg / mL, the concentration of anti-CD28 antibody is 0.01-500 μg / mL, and the concentration of interleukin-2 is 0.01-5000 ng / mL.

[0020] Preferably, the immersion temperature is 0 to 50° C. and the immersion time is 0 to 72 hours.

[0021] The invention provides a magnesium-containing hydrogel with T cell activation activity prepared by the above preparation method, comprising a hydrogel and nano magnesium oxide particles doped in the hydrogel, and a T cell activator compounded with the hydrogel.

[0022] The present invention provides application of the magnesium-containing hydrogel having T cell activation activity in preparing bone repair materials.

[0023] The present invention provides a method for preparing a magnesium-containing hydrogel with T cell activation activity, comprising the following steps: mixing nano magnesium oxide particles with a hydrogel raw material aqueous solution to obtain a hydrogel solution doped with magnesium oxide; adding a calcium chloride solution to the hydrogel solution doped with magnesium oxide to solidify and gel to obtain a hydrogel doped with magnesium oxide; immersing the hydrogel doped with magnesium oxide in a T cell activator solution to obtain a magnesium-containing hydrogel with T cell activation activity. The magnesium-containing hydrogel prepared by the present invention has a certain porosity, and can simultaneously slowly release the T cell activator and magnesium ions into the body to produce a bone repair effect. Magnesium ions are closely connected with bones and can promote osteogenesis. In the present invention, the nano magnesium oxide particles doped in the hydrogel slowly react with water molecules in the body to generate magnesium hydroxide. Since magnesium hydroxide has a low solubility in water, it can locally release magnesium ions; the presence of the T cell activator can promote the activation of T cells at the bone defect site, thereby enhancing the immune response. The present invention can regulate the biological environment of the bone defect site in a novel way. In the present invention, through the synergistic effect of nano magnesium oxide particles and T cell activators, the hydrogel can guide and regulate the immune response of the bone defect site in the initial stage, which is conducive to the regeneration and repair of bone tissue.

[0024] At the same time, the hydrogel material provided by the present invention can be used as a new type of therapeutic material for the repair and regeneration of bone defects, which is expected to reduce the treatment time and cost of patients; compared with traditional treatment methods, the hydrogel can provide better treatment effects, reduce the incidence of complications, and help reduce the consumption of medical resources and the treatment burden of patients. By promoting the initial T cell activation and immune regulation at the bone defect site, the hydrogel material provided by the present invention can promote the rapid repair and regeneration of bone tissue; the hydrogel is expected to become an important medical technology and have a positive social impact on the field of bone defect treatment.

[0025] In addition, the preparation method provided by the present invention is simple to operate, low in cost, and easy to realize industrial mass production. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 is a schematic diagram of preparing magnesium-based sodium alginate hydrogel containing T cell activator;

[0027] Figure 2 are bright field images and scanning electron microscope images of Gel, 0.25% Mg-Gel, 0.5% Mg-Gel, and 1.0% Mg-Gel;

[0028] Figure 3 It is the energy spectrometer scanning magnesium distribution of Gel, 0.25% Mg-Gel, 0.5% Mg-Gel, and 1.0% Mg-Gel;

[0029] Figure 4This is the magnesium ion release trend chart of 0.25% Mg-Gel, 0.5% Mg-Gel, and 1.0% Mg-Gel detected by ICP-OES;

[0030] Figure 5 It is a micro-CT 3D reconstruction image of rat skull and femur bone defects;

[0031] Figure 6 It is a quantitative data analysis of micro-CT bone mineral density (BMD), bone volume (BV) and bone volume ratio (BV / TV) of rat skull and femur bone defects. DETAILED DESCRIPTION

[0032] The present invention provides a method for preparing a magnesium-containing hydrogel having T cell activation activity, comprising the following steps:

[0033] Mixing nano-magnesium oxide particles with a hydrogel raw material aqueous solution to obtain a hydrogel solution doped with magnesium oxide;

[0034] Adding calcium chloride solution to the magnesium oxide-doped hydrogel solution to solidify the solution into a gel to obtain a magnesium oxide-doped hydrogel;

[0035] The magnesium oxide-doped hydrogel is immersed in a T cell activator solution to obtain a magnesium-containing hydrogel having T cell activation activity.

[0036] Unless otherwise specified, the raw materials used in the present invention are all commercially available.

[0037] The present invention preferably sterilizes the calcium chloride solution, nano magnesium oxide particles, and hydrogel raw material aqueous solution. In the present invention, the sterilization treatment preferably includes the following steps:

[0038] The calcium chloride solution, nano magnesium oxide particles and hydrogel raw material aqueous solution were placed in a high pressure steam sterilizer at a pressure of 103.4 kPa (1.05 kg / cm 2 ), temperature 121.3 ℃, maintain for 15 to 30 minutes to obtain sterile raw materials.

[0039] The present invention mixes nano magnesium oxide particles with a hydrogel raw material aqueous solution to obtain a hydrogel solution doped with magnesium oxide. In the present invention, the hydrogel raw material preferably includes one or more of collagen, gelatin, sodium alginate (SA), polyacrylic acid (PAA) and polyvinyl alcohol (PVA), more preferably sodium alginate.

[0040] In the present invention, the method for preparing the hydrogel raw material aqueous solution preferably comprises the following steps:

[0041] The hydrogel raw material and water are stirred and mixed to obtain a hydrogel raw material aqueous solution.

[0042] In the present invention, the water is preferably ultrapure water. In the present invention, the mass ratio of the hydrogel raw material to water is preferably 0.001 to 30:100, more preferably 0.01 to 20:100, further preferably 0.1 to 15:100, and further preferably 1 to 10:100.

[0043] In the present invention, the stirring is preferably carried out in a magnetic stirrer. In the present invention, the stirring rate is preferably 500-800 rpm, more preferably 600-700 rpm; the stirring temperature is preferably 60-70° C., more preferably 65° C., and the stirring time is preferably 30-60 min, more preferably 40-50 min.

[0044] As a specific embodiment of the present invention, when the hydrogel raw material is sodium alginate, the mass ratio of sodium alginate to ultrapure water is 2:100, the stirring rate is 500 rpm, the stirring temperature is 60° C., and the stirring time is 60 min.

[0045] In the present invention, the particle size of the nano-magnesium oxide particles is preferably 1 nm to 1 mm, more preferably 50 to 500 nm, and further preferably 50 to 100 nm. In the present invention, the mass ratio of the nano-magnesium oxide particles to the aqueous solution of the hydrogel raw material is preferably 0.001 to 20:100, more preferably 0.25 to 10:100, and more preferably 0.25 to 1:100. In the present invention, the mixing method of the nano-magnesium oxide particles and the aqueous solution of the hydrogel raw material is preferably stirring and mixing.

[0046] After obtaining the magnesium oxide-doped hydrogel solution, the present invention adds a calcium chloride solution to the magnesium oxide-doped hydrogel solution to solidify into a gel to obtain a magnesium oxide-doped hydrogel. In the present invention, the mass ratio of calcium chloride to water in the calcium chloride solution is preferably 1 to 5:10, more preferably 1 to 3:10, and further preferably 2:10. In the present invention, the volume ratio of the calcium chloride solution to the magnesium oxide-doped hydrogel solution is preferably 0.1 to 20:100, more preferably 5 to 10:100, and further preferably 6 to 8:100. In the present invention, the calcium chloride solution is preferably added dropwise.

[0047] In the present invention, the curing temperature is preferably 0-50°C, more preferably 10-40°C, more preferably 20-30°C; the time is preferably 0-30min, more preferably 10-20min. In the present invention, after curing, the obtained hydrogel doped with magnesium oxide is preferably washed in ultrapure water for 2-3 times.

[0048] After obtaining the hydrogel doped with magnesium oxide, the present invention soaks the hydrogel doped with magnesium oxide in a T cell activator solution to obtain a magnesium-containing hydrogel having T cell activation activity. In the present invention, the T cell activator solution is preferably a mixed aqueous solution of anti-CD3 antibody, anti-CD28 antibody, and interleukin-2. In the present invention, the anti-CD3 antibody is Ultra-LEAF Purified anti-mouse CD3ε, the anti-CD28 antibody is Ultra-LEAF Purifiedanti-mouse CD28, and the interleukin-2 is Recombinant Murine IL-2. As a specific embodiment of the present invention, the anti-CD3 antibody is purchased from BioLegend, the anti-CD28 antibody is purchased from BioLegend, and the interleukin-2 is purchased from ThermoFisher Scientific.

[0049] In the present invention, in the T cell activator solution, the concentration of anti-CD3 antibodies is preferably 1-3 μg / mL, more preferably 1-2 μg / mL; the concentration of anti-CD28 antibodies is preferably 3-10 μg / mL, more preferably 5-8 μg / mL; the concentration of interleukin-2 is preferably 10-30 ng / mL, more preferably 15-25 ng / mL.

[0050] In the present invention, the immersion temperature is preferably 0 to 50°C, more preferably 4 to 10°C, and the time is preferably 0 to 72h, more preferably 12 to 36h. In the present invention, the T cell activator and the hydrogel are mainly realized by electrostatic adsorption. The positively charged amino acid residues on the protein surface of the three T cell activators can form electrostatic attraction with the negative charge on the surface of the hydrogel, so that it is adsorbed on the hydrogel. This composite method can maintain weak binding while adsorbing and retaining the T cell activator, and can effectively disperse into the bone defect site after implantation in vivo and exert T cell activation.

[0051] The schematic diagram of the preparation of the magnesium-containing hydrogel having T cell activation activity of the present invention is as follows Figure 1 shown.

[0052] The invention provides a magnesium-containing hydrogel with T cell activation activity prepared by the above preparation method, comprising a hydrogel, nano magnesium oxide particles doped in the hydrogel, and a T cell activator compounded with the hydrogel.

[0053] In the present invention, the mesopore diameter of the magnesium-containing hydrogel with T cell activation activity is preferably 50 to 500 nm, more preferably 100 to 300 nm; the porosity is preferably 30 to 60%, more preferably 40 to 50%; the specific surface area is preferably 100 to 500 m 2 / g, more preferably 200 to 400 m 2 / g.

[0054] The magnesium-containing hydrogel prepared by the present invention has a certain porosity, and can slowly release T cell activators and magnesium ions into the body at the same time, producing a bone repair effect. In the present invention, the nano-magnesium oxide particles doped in the hydrogel can locally release magnesium ions; the presence of the T cell activator can promote the activation of T cells in the bone defect site, thereby enhancing the immune response. The present invention can regulate the biological environment of the bone defect site in a novel way; through the synergistic effect of nano-magnesium oxide particles and T cell activators, the hydrogel can guide and regulate the immune response of the bone defect site in the initial stage, which is conducive to bone tissue regeneration and repair.

[0055] The present invention provides application of the magnesium-containing hydrogel having T cell activation activity in preparing bone repair materials.

[0056] The magnesium-containing hydrogel with T cell activation activity provided by the present invention, its preparation method and application are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0057] Example 1

[0058] The preparation of 0.25% magnesium alginate hydrogel (0.25% Mg-Gel) was carried out using the following steps:

[0059] Step 1: Take 2 g of sodium alginate powder and add it to 100 mL of ultrapure water. Stir it in a magnetic stirrer at 70°C and 500 rpm for 30 min. Use plastic wrap to seal the mixture during stirring to prevent the liquid from evaporating. After stirring evenly, obtain a sodium alginate solution for use.

[0060] Step 2: Take 30g of pure calcium chloride crystals and add them to 70g of ultrapure water, stir with a glass rod until completely dissolved, and obtain a 30wt% calcium chloride solution for later use;

[0061] Step 3: Place the prepared sodium alginate solution, calcium chloride solution and nano magnesium oxide particles in a high pressure steam sterilizer at a pressure of 103.4 kPa (1.05 kg / cm 2 ), the temperature is 121.3°C, maintained for 15 to 30 minutes, to obtain sterile sodium alginate solution, calcium chloride solution and nano magnesium oxide particles for use;

[0062] Step 4: Weigh 0.25 g of 50 nm diameter nano-magnesium oxide particles and add them to 100 mL of sodium alginate solution and stir evenly. Use a rubber-tipped dropper to slowly add 10 mL of 30 wt% calcium chloride solution to the sodium alginate solution until it is completely gelled. The gelling temperature is 25 ° C and the curing time is 5 min. Use sterile ultrapure water to wash the sodium alginate hydrogel 2 to 3 times to obtain a sterile 0.25% magnesium sodium alginate hydrogel.

[0063] The prepared sodium alginate hydrogel was cut into suitable shapes and placed in a freeze dryer to dry the sample for 2 to 3 hours at -40 to -50 °C and 5 to 10 Pa. The prepared sample was used for scanning electron microscopy observation and characterization. The results are listed in Figure 2 , proving that the hydrogel can load magnesium nanoparticles while also having a certain degree of porosity.

[0064] Example 2

[0065] The preparation of 0.5% magnesium alginate hydrogel (0.5% Mg-Gel) was carried out using the following steps:

[0066] Step 1: Take 2 g of sodium alginate powder and add it to 100 mL of ultrapure water. Stir it in a magnetic stirrer at 70°C and 500 rpm for 30 min. Use plastic wrap to seal the mixture during stirring to prevent the liquid from evaporating. After stirring evenly, obtain a sodium alginate solution for use.

[0067] Step 2: Take 30g of pure calcium chloride crystals and add them to 70g of ultrapure water, stir with a glass rod until completely dissolved, and obtain a 30wt% calcium chloride solution for later use;

[0068] Step 3: Place the prepared sodium alginate solution, calcium chloride solution and nano magnesium oxide particles in a high pressure steam sterilizer at a pressure of 103.4 kPa (1.05 kg / cm 2 ), the temperature is 121.3°C, maintained for 15 to 30 minutes, to obtain sterile sodium alginate solution, calcium chloride solution and nano magnesium oxide particles for use;

[0069] Step 4: Weigh 0.5 g of 50 nm diameter nano-magnesium oxide particles and add them to 100 mL of sodium alginate solution and stir evenly. Use a rubber-tipped dropper to slowly add 10 mL of 30 wt% calcium chloride solution to the sodium alginate solution until it is completely gelled. The gelling temperature is 25 ° C and the curing time is 5 min. Use sterile ultrapure water to wash the sodium alginate hydrogel 2 to 3 times to obtain a sterile 0.5% magnesium sodium alginate hydrogel.

[0070] The prepared sodium alginate hydrogel was cut into suitable shapes and placed in a freeze dryer to dry the sample for 2 to 3 hours at -40 to -50 °C and 5 to 10 Pa. The prepared sample was used for scanning electron microscopy observation and characterization. The results are listed in Figure 2 , the hydrogel is accompanied by a relatively dispersed distribution of nanoparticles.

[0071] Example 3

[0072] The preparation of 1% magnesium alginate hydrogel (1.0% Mg-Gel) was carried out using the following steps:

[0073] Step 1: Take 2 g of sodium alginate powder and add it to 100 mL of ultrapure water. Stir it in a magnetic stirrer at 70°C and 500 rpm for 30 min. Use plastic wrap to seal the mixture during stirring to prevent the liquid from evaporating. After stirring evenly, obtain a sodium alginate solution for use.

[0074] Step 2: Take 30g of pure calcium chloride crystals and add them to 70g of ultrapure water, stir with a glass rod until completely dissolved, and obtain a 30wt% calcium chloride solution for later use;

[0075] Step 3: Place the prepared sodium alginate solution, calcium chloride solution and nano magnesium oxide particles in a high pressure steam sterilizer at a pressure of 103.4 kPa (1.05 kg / cm 2 ), the temperature is 121.3°C, maintained for 15 to 30 minutes, to obtain sterile sodium alginate solution, calcium chloride solution and nano magnesium oxide particles for use;

[0076] Step 4: Weigh 1.0 g of 50 nm diameter nano-magnesium oxide particles and add them to 100 mL of sodium alginate solution and stir evenly. Use a rubber-tipped dropper to slowly add 10 mL of 30 wt% calcium chloride solution to the sodium alginate solution until it is completely gelled. The gelling temperature is 25 ° C and the curing time is 5 min. Use sterile ultrapure water to wash the sodium alginate hydrogel 2 to 3 times to obtain a sterile 1% magnesium sodium alginate hydrogel.

[0077] The prepared sodium alginate hydrogel was cut into suitable shapes and placed in a freeze dryer to dry the sample for 2 to 3 hours at -40 to -50 °C and 5 to 10 Pa. The prepared sample was used for scanning electron microscopy observation and characterization. The results are listed in Figure 2, the hydrogel is accompanied by a large amount of dense, agglomerated magnesium nanoparticles distribution.

[0078] Comparative Example 1

[0079] The preparation of sodium alginate hydrogel (Gel) adopts the following steps:

[0080] Step 1: Take 2 g of sodium alginate powder and add it to 100 mL of ultrapure water. Stir it in a magnetic stirrer at 70°C and 500 rpm for 30 min. Use plastic wrap to seal the mixture during stirring to prevent the liquid from evaporating. After stirring evenly, obtain a sodium alginate solution for use.

[0081] Step 2: Take 30g of calcium chloride crystals and add them to 70g of ultrapure water, stir with a glass rod until completely dissolved, and obtain a 30wt% calcium chloride solution for later use;

[0082] Step 3: Place the prepared sodium alginate solution and calcium chloride solution in a high pressure steam sterilizer at a pressure of 103.4 kPa (1.05 kg / cm 2 ), the temperature is 121.3°C, maintained for 15 to 30 minutes, to obtain sterile sodium alginate solution and calcium chloride solution for use;

[0083] Step 4: Open the sterile sodium alginate solution and calcium chloride solution in a biosafety cabinet, and use a rubber-tipped dropper to slowly add 10 mL of 30 wt% calcium chloride solution to the sodium alginate solution until it is completely gelled. The gelling temperature is 25°C and the curing time is 5 minutes. Use sterile ultrapure water to wash the sodium alginate hydrogel 2 to 3 times to obtain a sterile sodium alginate hydrogel.

[0084] The prepared sodium alginate hydrogel was cut into suitable shapes and placed in a freeze dryer to dry the sample for 2 to 3 hours at -40 to -50 °C and 5 to 10 Pa. The prepared sample was used for scanning electron microscopy observation and characterization. The results are listed in Figure 2 , proving that the hydrogel has porosity.

[0085] Figure 2 The bright field images, scanning electron microscope images and energy dispersive spectrometer scanning of Mg-Gel, 0.25% Mg-Gel, 0.5% Mg-Gel and 1.0% Mg-Gel are shown in Figure 1. Figure 2It can be seen that the hydrogel without nano-magnesium oxide particles is transparent, and after being doped with MgO particles, the three hydrogel materials are milky white. 0.25% Mg-Gel and 0.5% Mg-Gel can maintain their original elasticity and water absorption. The results of scanning electron microscopy show that the cross-section of the Gel presents a porous and wrinkled morphology; with the increase of MgO content, 0.25% Mg-Gel, 0.5% Mg-Gel and 1% Mg-Gel can observe a gradually increasing number of nanoparticles. MgO is evenly dispersed in 0.25% Mg-Gel and 0.5% Mg-Gel, and EDS scanning also confirms its good dispersibility. Figure 3 The magnesium content ratio of the EDS scan is shown, which corresponds to the doping ratio.

[0086] The prepared 0.25% magnesium sodium alginate hydrogel, 0.5% magnesium sodium alginate hydrogel and 1% magnesium sodium alginate hydrogel were cut into the same shape and placed in three wells of a 6-well plate. Three replicates were prepared for each sample. 5 mL of ultrapure water was added to the wells to soak the samples. The top of the liquid surface was higher than the material. After soaking for 3, 24 and 72 hours, 500 μL of the leaching solution was taken for ICP-OES detection of magnesium ion release efficiency. The results are listed in Figure 4 It can be seen that 0.5% Mg-Gel and 1.0% Mg-Gel have similar magnesium ion release effects, with the magnesium ion concentration being approximately 4-5 mM at 72 h, while the magnesium ion release efficiency of 0.25% Mg-Gel is lower, with the final magnesium ion concentration being approximately 2 mM.

[0087] Example 4

[0088] The preparation of 0.25% magnesium sodium alginate hydrogel containing T cell activator (T-0.25% Mg-Gel) was carried out using the following steps:

[0089] A 0.25% magnesium sodium alginate hydrogel (0.25% Mg-Gel) was prepared according to the method of Example 1, and anti-CD3 antibody, anti-CD28 antibody and IL-2 were prepared into a T cell activation solution at concentrations of 1 μg / mL, 3 μg / mL and 10 ng / mL for standby use; the prepared sterile 0.25% magnesium sodium alginate hydrogel was soaked in the T cell activation solution at 4°C overnight to obtain a 0.25% magnesium sodium alginate hydrogel containing a T cell activator.

[0090] The prepared hydrogel was cut into suitable shapes for animal experiments. 12-week-old SD rats were selected, and skull and femur bone defect models were established using bone drill bits with a diameter of approximately 2 mm or 5 mm, respectively. The shaped materials were implanted into the bone defect sites and sutured, and micro-CT was taken 7 and 30 days after surgery.

[0091] Figure 5This is a micro-CT 3D reconstruction image of the rat skull and femur bone defects. Figure 6 It is a quantitative data analysis of micro-CT bone mineral density (BMD), bone volume (BV) and bone volume ratio (BV / TV) of rat skull and femur bone defects. Figure 5 The GeL-Mg in the gel is 0.25% Mg-Gel, Figure 4 The preparation method of GeL-T is as follows:

[0092] The preparation of sodium alginate hydrogel (T-Gel) containing T cell activator is carried out by the following steps:

[0093] Sodium alginate hydrogel (Gel) was prepared according to the method of Comparative Example 1, and anti-CD3 antibody, anti-CD28 antibody and IL-2 were prepared into T cell activation solution at concentrations of 1 μg / mL, 3 μg / mL and 10 ng / mL for use; the prepared sterile sodium alginate hydrogel was immersed in the T cell activation solution at 4°C overnight to obtain a sodium alginate hydrogel containing a T cell activator.

[0094] Figure 5 The repair of bone defects in the femur and skull implanted with magnesium-based sodium alginate hydrogel composites is shown. As shown in the figure, on the 7th day of repair, all femoral holes had a certain degree of trabecular bone formation, and the outer cortical bone did not grow significantly. The cortical bone on the outer side of the drilled hole in the T-0.25% Mg-Gel group had a certain degree of hyperplasia, covering part of the bone defect pores. There was no significant difference in bone repair between the groups in the skull defect. On the 30th day of bone repair, the defect area in the T-0.25% Mg-Gel group was almost unobservable, and the outer side repair was better; both the 0.25% Mg-Gel group and the T-Gel group had strong cortical bone hyperplasia, but it could still be observed that some defect areas were not completely healed; the Gel group showed a lower repair efficiency, and the cortical bone only occurred to a certain extent at the edge of the pore, and there was still a certain range of defects.

[0095] Figure 6The bone density (BMD), bone volume (BV) and bone volume fraction (BV / TV) of the skull and femur implanted with hydrogel composites were analyzed based on the micro-CT image results. The results showed that the T-0.25% Mg-Gel group showed significant differences in all bone tissue evaluation indicators (*P<0.05, **P<0.01, ****P<0.0001). In the bar graphs of BMD of the skull and femur, BV of the skull and femur, and BV / TV of the femur, the T-0.25% Mg-Gel group had the most significant differences compared with the other groups (***P<0.001, ****P<0.0001). The results showed that T-0.25% Mg-Gel had better osteogenic performance and bone immunomodulatory effect. Although the 0.25% Mg-Gel group and the T-Gel group also showed certain bone regeneration performance in some indicators, the bone healing performance of these materials was still incomplete according to indicators such as implantation position, repair density and bone volume. The results showed that T-0.25% Mg-Gel had the best bone regeneration performance.

[0096] Due to the faster biodegradation rate of hydrogels, Mg 2+ After being released into the bone defect microenvironment, it can regulate the inflammatory response in the early stage of repair; at the same time, the T cell activating factor in the hydrogel can activate the T cells that enter by chemotaxis, induce these cells to activate and proliferate in the defect area, and exert an immune regulatory effect. 2+ The dual bone immune regulatory effects of T cells and T cells can regulate the inflammatory response in the early stage of bone defect repair and promote bone healing and bone growth in the long term.

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing a magnesium-containing hydrogel having T cell activation activity, comprising the following steps: Mixing nano-magnesium oxide particles with a hydrogel raw material aqueous solution to obtain a hydrogel solution doped with magnesium oxide; Adding calcium chloride solution to the magnesium oxide-doped hydrogel solution to solidify the solution into a gel to obtain a magnesium oxide-doped hydrogel; The magnesium oxide-doped hydrogel is immersed in a T cell activator solution to obtain a magnesium-containing hydrogel having T cell activation activity.

2. The preparation method according to claim 1, characterized in that: The hydrogel raw materials include one or more of collagen, gelatin, sodium alginate, polyacrylic acid and polyvinyl alcohol; In the hydrogel raw material aqueous solution, the mass ratio of the hydrogel raw material to water is 0.001 to 30:

100.

3. The preparation method according to claim 1, characterized in that: The particle size of the nano magnesium oxide particles is 1 nm to 1 mm.

4. The preparation method according to claim 1 or 3, characterized in that: The mass ratio of the nano magnesium oxide particles to the hydrogel raw material aqueous solution is 0.001 to 20:

100.

5. The preparation method according to claim 1, characterized in that: The mass ratio of calcium chloride to water in the calcium chloride solution is 1 to 5:10; The volume ratio of the calcium chloride solution to the hydrogel solution doped with magnesium oxide is 0.1 to 20:

100.

6. The preparation method according to claim 1, characterized in that: The curing temperature is 0 to 50° C. and the curing time is 0 to 30 minutes.

7. The preparation method according to claim 1, characterized in that: The T cell activator solution is a mixed aqueous solution of anti-CD3 antibody, anti-CD28 antibody and interleukin-2; In the T cell activator solution, the concentration of anti-CD3 antibody is 0.01-500 μg / mL, the concentration of anti-CD28 antibody is 0.01-500 μg / mL, and the concentration of interleukin-2 is 0.01-5000 ng / mL.

8. The preparation method according to claim 1 or 7, characterized in that: The immersion temperature is 0-50°C and the immersion time is 0-72h.

9. The magnesium-containing hydrogel having T cell activation activity prepared by the preparation method according to any one of claims 1 to 8, comprising a hydrogel and nano-magnesium oxide particles doped in the hydrogel, and a T cell activator compounded with the hydrogel.

10. Use of the magnesium-containing hydrogel having T cell activation activity according to claim 9 in the preparation of bone repair materials.